Valuation : BioCardia, Inc.

Market Cap 16.65M 14.33M 13.49M 12.29M 23M 1.58B 23.09M 160M 61.8M 807M 62.53M 61.17M 2.56B P/E 2026 *
-1.75x
P/E 2027 * -2.14x
Enterprise Value 16.65M 14.33M 13.49M 12.29M 23M 1.58B 23.09M 160M 61.8M 807M 62.53M 61.17M 2.56B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
76.81%
Yield 2026 *
-
Yield 2027 * -
1 day-0.90%
1 week-0.90%
Current month-3.51%
1 month+12.44%
3 months+27.95%
6 months-14.06%
Current year-12.00%
1 week 1.06
Extreme 1.06
1.14
1 month 0.85
Extreme 0.8521
1.23
Current year 0.75
Extreme 0.75
1.8
1 year 0.75
Extreme 0.75
2.29
3 years 0.75
Extreme 0.75
23.25
5 years 0.75
Extreme 0.75
59.4
10 years 0.75
Extreme 0.75
2,073.6
Manager TitleAgeSince
Chief Executive Officer 59 2001-12-31
Director of Finance/CFO 62 2016-02-29
Chief Tech/Sci/R&D Officer - 2017-07-31
Director TitleAgeSince
Director/Board Member 59 2001-12-31
Director/Board Member 72 2010-12-31
Chairman 90 2001-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.90%-0.90%-47.87%-84.06% 16.65M
-0.94%-0.71%+45.60%+103.25% 68.52B
-0.39%-5.55%+31.41%+75.27% 62.88B
+3.13%+1.71%-12.50%+390.48% 28.13B
-2.95%-6.51%+26.06%+11.01% 25.56B
-0.54%-5.47%-3.88%-18.31% 24.65B
-1.10%-3.64%+19.67%-18.33% 19.81B
-4.27%+3.07%+211.22%+362.48% 17.69B
-1.66%-4.51%-5.21%+507.43% 14.66B
+1.14%-0.34%+52.38%+163.82% 14.45B
Average -0.82%-1.37%+31.69%+149.30% 27.64B
Weighted average by Cap. -0.69%-1.87%+36.64%+139.22%

Financials

2026 *2027 *
Net sales - -
Net income -8.7M -7.49M -7.05M -6.42M -12.02M -828M -12.07M -83.55M -32.29M -422M -32.67M -31.96M -1.34B -9.94M -8.55M -8.05M -7.34M -13.73M -946M -13.78M -95.45M -36.89M -482M -37.32M -36.51M -1.53B
Net Debt - -
Logo BioCardia, Inc.
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Employees
19
Date Price Change Volume
26-09-09 US$1.100 -0.90% 91,021
26-09-08 US$1.110 +2.78% 130,312
26-09-04 US$1.080 -0.92% 58,196
26-09-03 US$1.090 -1.80% 169,600
26-09-02 US$1.110 +0.91% 50,969
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.100USD
Average target price
15.50USD
Spread / Average Target
+1,309.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCDA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!